Methocarbamol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Methocarbamol: From Musculoskeletal Conditions to Cauda Equina Syndrome
One-Sentence Summary
Methocarbamol is a centrally acting skeletal muscle relaxant that is marketed in the United States as oral tablets and an injectable solution. The TxGNN model predicts it may be effective for Cauda Equina Syndrome, but 0 clinical trials and 0 publications currently support this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the supplied license records (methocarbamol is a skeletal muscle relaxant) |
| Predicted New Indication | Cauda equina syndrome |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (the listed authorizations are generic ANDAs) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, methocarbamol is a centrally acting skeletal muscle relaxant whose mechanism is incompletely characterized. Its effect on muscle spasm and back pain may be applicable to symptoms that accompany lumbosacral pathology.
The link to cauda equina syndrome is weak and symptomatic only. The condition is caused by compression of the nerve roots at the lower end of the spinal canal, and it is a surgical emergency. Methocarbamol would not treat that compression. At most it might ease accompanying muscle spasm or pain.
The TxGNN score of 99.98% is a model prediction, not clinical evidence. It should not be read as proof of efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA040489 | Methocarbamol (Bryant Ranch Prepack) | Tablet | Not stated in the supplied records |
| ANDA200958 | Methocarbamol (Oncora Pharma, LLC) | Tablet, coated | Not stated in the supplied records |
| ANDA209312 | Methocarbamol (Granules India Ltd) | Tablet, coated | Not stated in the supplied records |
| ANDA040489 | Methocarbamol (PD-Rx Pharmaceuticals, Inc.) | Tablet | Not stated in the supplied records |
| ANDA200958 | Methocarbamol (Bostal LLC) | Tablet, coated | Not stated in the supplied records |
Other available forms: film-coated oral tablets and an injectable solution.
Safety Considerations
Please refer to the package insert for safety information. No warnings or contraindications were available, and no drug interactions were found in the queried source.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trials or literature behind it (Evidence Level L5, screening stage S0). Methocarbamol could at best relieve symptoms and would not address the cause of cauda equina syndrome, which needs urgent surgical care.
The other nine predictions (irritable bowel syndrome, panuveitis, anaphylaxis, iris disease, uveitis, ventricular tachycardia, food-dependent exercise-induced anaphylaxis, conjunctivitis, and obsolete bundle branch block) are also L5 and Hold. Two articles were retrieved for them, but neither evaluates methocarbamol for the predicted condition: a general review of arthropod bites and stings (anaphylaxis) and a veterinary lamotrigine toxicosis case report (ventricular tachycardia). Several of these predictions have no plausible mechanistic link.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data, for example from DrugBank
- Approved indication text for the US licenses
- Clinical or preclinical studies of methocarbamol in cauda equina syndrome or related radiculopathy pain
- Route compatibility and similarity-to-original assessments, both still pending
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.